Page 19 - ARNM-2-4

Advances in Radiotherapy
& Nuclear Medicine Radionuclide-carrying liposomes

nanoparticles. Adv Drug Deliv Rev. 2014;76:39-59. [RGBM] via Convection Enhanced Delivery (CED). Neuro
Oncol. 2023;25:v86.
doi: 10.1016/j.addr.2014.07.001
doi: 10.1093/neuonc/noad179.0332
44. Christenson C, Wu C, Hormuth DA 2 , Huang S, Bao A,
nd
Brenner A, Yankeelov TE. Predicting the spatio-temporal 47. Brenner A, Youssef M, LaFrance N, et al. LOCL-04 safety
response of recurrent glioblastoma treated with rhenium-186 and feasibility of rhenium-186 nanoliposome ( rnl) in
186
labelled nanoliposomes. Brain Multiphys. 2023;5:100084. leptomeningeal metastases [lm] phase 1/2a dose escalation
trial. Neurooncol Adv. 2022;4(Suppl 1):i12.
doi: 10.1016/j.brain.2023.100084
doi: 10.1093/noajnl/vdac078.046
45. Wu C, Hormuth DA 2 , Christenson CD, et al. Image-
nd
guided patient-specific optimization of catheter placement 48. Chang CH, Chang MC, Chang YJ, Chen LC, Lee TW,
for convection-enhanced nanoparticle delivery in recurrent Ting G. Translating research for the radiotheranostics of
glioblastoma. Comput Biol Med. 2024;179:108889. nanotargeted re-liposome. Int J Mol Sci. 2021;22(8):3868.
188
doi: 10.1016/j.compbiomed.2024.108889 doi: 10.3390/ijms22083868
46. Brenner A, Michalek J, Moore M, et al. Update report of 49. Phillips WT, Klipper R, Goins B. Novel method of greatly
the RESPECT-GBM phase I/IIA dose escalation trial of enhanced delivery of liposomes to lymph nodes. J Pharmacol
rhenium-186 nanoliposome ( RNL) in recurrent glioma Exp Ther. 2000;295(1):309-313.
186

Volume 2 Issue 4 (2024) 11 doi: 10.36922/arnm.4373